BAX vs OMCL: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BAX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BAX and OMCL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BAX and OMCL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. After decades as a sprawling healthcare conglomerate, Baxter reshaped itself: it spun off and then sold its Kidney Care segment (rebranded Vantive) to Carlyle for roughly $3.8 billion, using proceeds to reduce debt. What remains is a company centered on Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals, serving hospitals worldwide with high-volume, mission-critical supplies.

Full BAX guide

Omnicell, Inc. (NASDAQ: OMCL) is a healthcare-technology company that builds medication-management and pharmacy-automation systems for hospitals, health systems, retail and specialty pharmacies, and other care settings. Its core products include automated dispensing cabinets (the XT and XR series), central-pharmacy robotics, IV compounding automation, and a growing layer of cloud software and services branded around what the company calls the Autonomous Pharmacy. Omnicell earns money from product sales (the hardware and installed systems) and from a rising base of recurring service and subscription revenue, including its Advanced Services and technician-enabled offerings, and it tracks annual recurring revenue (ARR) and product bookings as key operating metrics.

Full OMCL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BAX drivers: Margin and operational turnaround; Deleveraging after the Vantive sale.
• OMCL drivers: Shift toward recurring software and services; Large installed base and replacement cycle.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. For OMCL, omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BAX if you believe its drivers more; OMCL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BAX and OMCL guides.

BAX. Baxter trades at a modest valuation (price-to-sales near 1x) that reflects both its low-growth profile and the balance-sheet overhang. Full-year 2026 guidance calls for roughly flat to 1% sales growth on a GAAP basis. Reported profitability has been distorted by special charges, so adjusted metrics tell a more stable story than headline GAAP figures.

OMCL. Omnicell trades around $43 per share for a market capitalization near $1.96 billion as of July 2026, with a wide 52-week range that reflects how sensitive the stock is to bookings and margin trends. The trailing GAAP P/E has been very high (around 97) because GAAP earnings have been depressed, while normalized or forward multiples on non-GAAP EPS are far lower (Morningstar cited a normalized P/E near 22). That gap between GAAP and non-GAAP earnings is central to how different investors value the name.

Headline figures (approximate, July 2026): BAX shows revenue (ttm, continuing ops) ~$10.7B, q1 2026 sales ~$2.7B, q1 2026 adjusted eps ~$0.36, market cap ~$11.5B; OMCL shows revenue (fy2025) ~$1.185 billion (up ~7%), non-gaap ebitda (fy2025) ~$140 million, revenue (q1 2026) ~$310 million (up ~15% YoY), non-gaap eps (q1 2026) ~$0.55 (vs ~$0.26 a year earlier).

BAX and OMCL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BAX and OMCL exposure against your real portfolio. It is not an investment adviser.